Resources

Access Our Research Documentation

Enter your email to view the laboratory testing and clinical documentation behind BIOAELUS™.

The BIOAELUS™ technology (originally developed and laboratory-tested under the name "Bioscreen") is supported by laboratory antimicrobial testing and early clinical observation. The table below describes what each document actually is and what it demonstrates, so the evidence can be read in its proper context.

Laboratory Antimicrobial Testing — BIOAELUS™ Raw Ingredient

Document Test Type Result What This Means
EN 1040 (RAP.1040.559.HBA.07.1.v2), Biotech-Germande, COFRAC-accredited, 2008 In-vitro suspension test (5-minute contact) — a standardized method for evaluating basic bactericidal activity of chemical antiseptics and disinfectants ≥5.0–5.2 log reduction of S. aureus and P. aeruginosa at 24% concentration Confirms antimicrobial activity of the raw BIOAELUS™ ingredient under controlled laboratory conditions. This is a disinfectant-standard test, not a study of oral supplement effects in the human body.
EN 1275 (RAP.1275.559.HBA.07.v2), Biotech-Germande, 2008 In-vitro suspension test (15-minute contact) — the equivalent standard for basic fungicidal/yeasticidal activity >4.4 log reduction of Candida albicans at 20–24% concentration Laboratory antifungal test on the raw ingredient. Not a test of gut, skin, or respiratory outcomes in humans.
EN 13727 (RAP.13727.591.HBA.08.1), Biotech-Germande, 2009 In-vitro suspension test under "dirty conditions" (60-minute contact) — the standard specifically used to evaluate chemical disinfectants for medical instruments ≥5.4–5.6 log reduction of P. aeruginosa, S. aureus and E. hirae at 53–80% concentration This standard evaluates surface/instrument disinfection, not oral or topical product efficacy in the body.
NSF International / Toxicology Group laboratory report, 2003 In-vitro flask test against P. aeruginosa, a bacterium relevant to bottled water and plumbing contamination >5 log reduction within 4 hours Laboratory water/surface-contamination test on the raw ingredient, unrelated to human clinical outcomes.
NSF International / Toxicology Group laboratory report, 2003 In-vitro flask test against Penicillium oxalicum, a common airborne mold found on building materials >3.1 log reduction within 24 hours Laboratory mold test relevant to environmental/building contexts, not human clinical outcomes.
NSF International / Toxicology Group laboratory report, 2003 In-vitro flask test against Stachybotrys chartarum ("black mold"), an environmental contaminant found on textiles and building materials >3.9 log reduction within 4 hours Laboratory mold test relevant to environmental/building contexts, not human clinical outcomes.
NSF International / ATS Labs (The Toxicology Group), 2003 In-vitro virucidal suspension test against Human Coronavirus (ATCC VR-740, Strain 229E), a common-cold coronavirus strain used in the lab as a surrogate for evaluating antiviral activity ≥99.97% (≥3.6 log reduction) in viral titer at 10-minute exposure; ≥99.4% (≥2.2 log reduction) at 24-hour exposure Laboratory antiviral test on the raw ingredient using a common-cold coronavirus surrogate strain in a controlled suspension assay. Not a study of respiratory infection prevention or treatment in humans, and not evidence of effect against any specific virus, including SARS-CoV-2.
Institut Pasteur de Lille (NC/0380402), 2002 In-vitro minimal inhibitory concentration (MIC) test against Pseudomonas aeruginosa, Staphylococcus aureus, Candida albicans and Aspergillus niger Minimal inhibitory concentration ranged from 1.7% (S. aureus, C. albicans) to 12.5% (A. niger); overall minimum inhibitory concentration of 12.5% across all 4 strains tested Laboratory antimicrobial/antifungal screening test on the raw ingredient. Not a study of oral supplement effects or infection outcomes in humans.
Institut Pasteur de Lille (NC/0460303), 2003 In-vitro antibacterial activity test against Mycobacterium tuberculosis (ATCC 25177) Inhibition halo observed around the powder at all concentrations tested (0.5 g, 0.25 g, 0.1 g) Laboratory antibacterial test on the raw ingredient against a single bacterial species in a controlled culture setting. Not a study of tuberculosis prevention, treatment, or any human clinical outcome.

Early Clinical Observation — Topical & Oral Use

Document Study Type Findings What This Means
Dr. Ryan Carlson Grekin, Skin Institute, Wyandotte, Michigan, 2012 (technology then named "Bioscreen," now BIOAELUS™) Informal case series of 3 individual acne patients treated topically and orally in the physician's own practice, followed over 1–3 months All three patients showed a reduction in inflammatory acne lesions over the observation period, with no adverse effects reported This is a small, uncontrolled physician case series — not a peer-reviewed or independently verified clinical trial. It is shared here for transparency about the technology's development history, not as proof of efficacy for any specific product.